Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study With a Phase 2 Expansion Cohort of Zandelisib and Tazemetostat in Relapsed or Refractory Follicular Lymphoma

NCT05604417 is registered in ClinicalTrials.gov with Jacob Soumerai, MD as lead sponsor.

NCT NCT05604417
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05604417 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study With a Phase 2 Expansion Cohort of Zandelisib and Tazemetostat in Relapsed or Refractory Follicular Lymphoma
Lead sponsor
Jacob Soumerai, MD
Phase
Phase 1/2
Overall status
Withdrawn
Start date
January 31, 2023
Completion date
December 1, 2026
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

refractory follicular lymphoma, relapsed follicular lymphoma